INIS
patients
100%
plasma
55%
concentration
46%
anticoagulants
46%
laboratories
39%
monitoring
39%
risks
33%
heparin
33%
reagents
31%
thrombin
30%
comparative evaluations
27%
prothrombin
23%
sensitivity
23%
levels
23%
assessments
21%
management
20%
thromboplastin
20%
reviews
19%
tissues
19%
evaluation
18%
diseases
18%
neutrophils
18%
drugs
17%
doses
16%
blood cells
14%
surgery
12%
vitamin k
12%
venoms
11%
performance
11%
recommendations
11%
applications
11%
electrodes
11%
liquids
10%
inflammation
10%
leukemia
10%
phospholipids
10%
dimers
9%
fibrinogen
8%
therapy
8%
capacity
8%
thrombosis
8%
molecular weight
8%
morphology
7%
correlations
7%
control
7%
screening
7%
values
7%
surveys
6%
proteins
6%
peaks
6%
Medicine and Dentistry
Procoagulant
22%
Heparin
20%
Blood Stasis
15%
Heparin-Induced Thrombocytopenia
12%
Volunteer
11%
Thrombosis
11%
COVID-19
11%
Venous Thromboembolism
10%
Thrombin
10%
Serositis
8%
Thromboplastin
7%
Platelet
7%
D-Dimer
7%
Disseminated Intravascular Coagulation
7%
Anticoagulation
6%
Neutrophil
6%
Biological Marker
6%
Retrospective Study
5%
Erythrocyte Concentrate
5%
Paroxysmal Nocturnal Hemoglobinuria
5%
Apixaban
5%
Acute Leukemia
5%
Myelodysplastic Syndrome
5%
Clonidine
5%
Alpha 2 Adrenergic Receptor Stimulating Agent
5%
Edoxaban
5%
Microparticle
5%
Coagulopathy
5%
Azathioprine
5%
Injury
5%
Emergency Department
5%
Hirudin
5%
Tissue Factor Pathway Inhibitor
5%
Fibrinolysis
5%
Hemophagocytosis
5%
Hereditary Spherocytosis
5%
Reticulocyte
5%
Nanomaterial
5%
Low Molecular Weight Heparin
5%
Prothrombin Time
5%
Laboratory Test
5%
Keyphrases
Del(20q)
11%
Myelodysplasia
11%
Dabigatran
11%
Atrial Fibrillation
11%
Dabigatran Etexilate
10%
Myelodysplastic Syndrome
8%
Erythrophagocytosis
7%
Thrombophilia Screening
5%
Laboratory Evaluation
5%
Hemostasis Laboratory
5%
Rivaroxaban
5%
Rapid Estimation
5%
Neutrophils
5%
Dilute Russell's Viper Venom Time
5%
Edoxaban
5%
Paroxysmal Nocturnal Hemoglobinuria
5%
Crohn's Disease
5%
Age-adjusted Cutoff
5%
D-dimer
5%
Acute Leukemia
5%
Therapy-related Myeloid Neoplasms
5%
Heparin Monitoring
5%
Emergency Department
5%
Platelet-derived Microparticles
5%
Promyelocytic
5%
Hypercoagulable State
5%
Procoagulant Activity
5%
Time-based
5%
Heparin-induced Thrombocytopenia
5%
Acute Injury
5%
AcuStar
5%
Heparin-induced multiple Electrode Aggregometry
5%
Trauma-induced Coagulopathy
5%
Coagulation Disorders
5%
Extracellular Vesicles
5%
α2-adrenergic Agonist
5%
Early Reperfusion
5%
Longitudinal Clinical Study
5%
Prospective Longitudinal Study
5%
Preoperative Setting
5%
Hemoclot Thrombin Inhibitor Assay
5%
Tissue Characterization
5%
Peak Force
5%
Tapping Mode Atomic Force Microscopy
5%
Clonidine
5%
Tissue Factor Pathway inhibitor-2 (TFPI-2)
5%
Activated Partial Thromboplastin Time (aPTT)
5%
Coagulation Assays
5%
Practical Laboratories
5%
Chromogenic anti-Xa Assay
5%